Log In
Print
BCIQ
Print
Print this Print this
 

LBR-101 (formerly RN-307)

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionHumanized mAb that blocks the calcitonin gene-related peptide (CGRP) from binding to its receptor
Molecular Target Calcitonin gene-related peptide (CGRP)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationMigraine
Indication DetailsTreat chronic migraine; Treat high frequency episodic migraine
Regulatory Designation

Partner

Teva Pharmaceutical Industries Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today